Patent Application
20180251835
One or more embodiments of the present invention relate to a nucleic acid detection device and a nucleic acid detection method.
With progression of genetic engineering, genetic tests have been used in detection of pathogens or cancer cells, the analysis of the cell kinetics, constitution inspections, tests regarding the effectiveness of pharmaceutical products, etc. The genetic test is generally composed of a step of collecting a specimen, a step of preparing a nucleic acid from the specimen, a nucleic acid amplification reaction step and/or a nucleic acid labeling reaction step, and a step of detecting the amplified and/or labeled nucleic acid.
Regarding the detection step, nucleic acid detection devices, such as lateral flow-type (Patent Literature 1), dip stick-type (Patent Literature 2) and array-type (Patent Literature 3) nucleic acid detection devices, which are capable of capturing and/or detecting the amplified and/or labeled nucleic acid on a solid phase carrier, have been developed and utilized. In general, these nucleic acid detection devices each comprise a target detection portion for detecting the amplified and/or labeled reaction product of the target nucleic acid, and a control detection portion for detecting the amplified and/or labeled reaction product of a control nucleic acid (internal standard substance) that has been added as a control in advance. The control detection portion is used to evaluate whether the amplification reaction and/or labeling reaction have normally progressed. Specifically, detecting signals in the control detection portion can evaluate whether reagents such as enzymes have functioned normally and whether experimental operations have been implemented appropriately, and the reliability of the test results can be confirmed.
Regarding conventional nucleic acid detection devices, the present inventors have thought that signals, which should have been obtained in the control detection portion of such a conventional nucleic acid detection device, are likely to disappear or decrease, even when there are no issues regarding reagents or experimental operations.
The present inventors have surprisingly elucidated that when large quantities of target nucleic acids are present in a reaction system, for example, in multiplex PCR, etc., there is a case where the target nucleic acids may be amplified, and the amplification reaction and/or labeling reaction of control nucleic acids are inhibited, so that signals from a control detection portion would disappear or weaken.
Moreover, the present inventors have found that when not only a control nucleic acid, but also at least one type of target nucleic acid is captured and/or detected in the control detection portion of a nucleic acid detection device, the disappearance or reduction of signals from the control detection portion can be prevented, and high signals can be stably obtained. Furthermore, the present inventors have provided a nucleic acid detection device utilizing this finding.
Specifically, one or more embodiments of the present invention are as follows.
(1) A nucleic acid detection device comprising at least one target detection portion and a control detection portion, wherein a probe for capturing a target nucleic acid (“first probe”) is immobilized on the target detection portion, and a probe for capturing a control nucleic acid (“second probe”) and at least one probe for capturing the target nucleic acid (“third probe”) are immobilized on the control detection portion.
(2) In one or more embodiments of the present invention the nucleic acid detection device according to the above (1), the target nucleic acid and the control nucleic acid are amplification reaction products that have undergone an amplification step.
(3) In one or more embodiments of the present invention the nucleic acid detection device according to the above (1) or the nucleic acid detection device in one or more embodiments according to the above (2), the probe is a nucleic acid or a protein.
(4) In one or more embodiments of the nucleic acid detection device according to the above (1) or the nucleic acid detection device in one or more embodiments according to the above (2) or (3), the device is a chromatographic device.
(5) A nucleic acid detection kit comprising the nucleic acid detection device according to the above (1) or the nucleic acid detection device in one or more embodiments according to any one of the above (2) to (4), a control template nucleic acid, a nucleic acid amplification enzyme, a nucleic acid amplification reaction reagent, and a nucleic acid detection reaction reagent.
(6) A nucleic acid detection method for detecting at least one target nucleic acid and a control nucleic acid, which comprises the following steps (a) to (d):
(a) a step of simultaneously performing a nucleic acid amplification reaction in a single reaction vessel, using primers, a template nucleic acid and a nucleic acid amplification reaction reagent, so as to amplify the at least one target nucleic acid and the control nucleic acid,
(b) a step of allowing the at least one target nucleic acid to bind to a probe immobilized on a target detection portion on a solid phase carrier,
(c) a step of allowing the at least one target nucleic acid and the control nucleic acid to bind to at least one probe immobilized on a control detection portion on the solid phase carrier, and
(d) a step of labeling the captured target nucleic acid and control nucleic acid, and detecting signals derived from the target nucleic acid and the control nucleic acid.
(7) In one or more embodiments of the nucleic acid detection method according to the above (6), the probe is a nucleic acid or a protein.
The present description includes the contents as disclosed in Japanese Patent Application No. 2015-167198, which is a priority document of the present application.
According to one or more embodiments of the present invention, since the disappearance or reduction of signals from a control detection portion in a nucleic acid detection device can be prevented and high signals can be stably obtained, the reliability of test results can be easily confirmed.
One or more aspects of collection of a specimen, preparation of a nucleic acid from the specimen, amplification of the nucleic acid, and detection of the nucleic acid, which can be used in the nucleic acid detection method as described herein, will be described below.
The specimen used as an analyte, in which the presence of a target nucleic acid is to be detected, is not particularly limited, as long as it is a sample possibly containing the nucleic acid. Examples of such a specimen include animal or plant cells, tissues, whole blood, serum, body fluids such as lymph fluid, bone marrow fluid, tissue fluid, urine, sperm, vaginal fluid, amniotic fluid, tear, saliva, sweat or milk juice, cell-derived vesicles such as exosome, feces, throat swab, phlegm, bacteria, virus, and viroid. For collection of a specimen, various types of conventionally known methods can be used.
The nucleic acid used in one or more embodiments of the present invention is broadly classified into natural nucleic acid and non-natural nucleic acid. The “natural nucleic acid” is a polynucleotide comprising nucleotides as basic portions, wherein the nucleotides are bound to one another by a phosphodiester bond that is a linkage between the 3′ carbon atom of one sugar molecule and the 5′ carbon atom of another sugar. Examples of the natural nucleic acid include deoxyribonucleotides such as DNA or RNA, and polymers of ribonucleotides. The “non-natural nucleic acid” is a nucleic acid comprising non-natural nucleotides, instead of or in addition to the above-described natural nucleotides. The non-natural nucleotide indicates a nucleotide, the basic portion or other portion of which has been artificially modified, or an artificially produced nucleotide analog having properties similar to those of a nucleotide. Examples of the non-natural nucleotide include xanthosines and diaminopyrimidines.
The target nucleic acid used in one or more embodiments of the present invention is a nucleic acid to be detected. The present target nucleic acid is not particularly limited, as long as it comprises a target sequence. Examples of the present target nucleic acid include the aforementioned specimen-derived genomic DNA, plasmid DNA, ctDNA (cfDNA), mRNA, miRNA, lncRNA, and an amplicon. In the present description, an amplification reaction product obtained by amplification of a target nucleic acid contained in a specimen may also be referred to as a “target nucleic acid.”
The control nucleic acid used in one or more embodiments of the present invention is a nucleic acid used as an internal standard for confirming that operations or reagents are not problematic upon detection of a target nucleic acid. The present control nucleic acid is not particularly limited, as long as it exhibits the aforementioned function. In one or more embodiments of the present invention, an amplification reaction product obtained by amplification of a control nucleic acid added as a template nucleic acid to a nucleic acid amplification reaction system may also be referred to as a “control nucleic acid.”
<Step of Preparing Nucleic Acid from Specimen>
In a step of preparing a nucleic acid used as a template nucleic acid in the below-described step (a) from a specimen, a nucleic acid may be extracted, or separated and/or purified from a specimen. The means are not particularly limited. Examples of the extraction method include physical disintegration such as the use of heat or ultrasonic waver, disintegration using drugs such as an alkaline reagent, an organic solvent or a surfactant, and disintegration using enzymes such as lysozyme or proteinase K. Examples of the separation and/or purification include a bind-elute method, a treatment using an ion exchange resin such as zeolite, and centrifugation. However, the step of preparing a nucleic acid from a specimen is not particularly limited, as long as the prepared nucleic acid can be used as a template nucleic acid and the subsequent biochemical reactions such as a nucleic acid amplification reaction can progress without difficulties. Moreover, it is also possible to omit the present step and to directly subject a specimen as a supply source of a template nucleic acid to the subsequent nucleic acid amplification reaction.
<Step of Amplifying Nucleic Acid (Step (a))>
Step (a) of the method as described herein is a step of using primers, a template nucleic acid and a nucleic acid amplification reaction reagent (nucleic acid amplification reagent) to simultaneously perform a nucleic acid amplification reaction in a single reaction vessel, so as to amplify the above-described at least one target nucleic acid and the above-described control nucleic acid.
In step (a), the template nucleic acid comprises nucleic acids possibly including target nucleic acids (typically, nucleic acids derived from the above-described specimen) and a control nucleic acid. The control nucleic acid, which is to be added as a template nucleic acid to the nucleic acid amplification reaction system, is also referred to as a “control template nucleic acid.”
The phrase “simultaneously perform a nucleic acid amplification reaction in a single reaction vessel” is used to mean that the nucleic acid amplification reaction of the above-described at least one target nucleic acid and the nucleic acid amplification reaction of the above-described control nucleic acid are simultaneously performed in a single reaction vessel. Hence, primers used in step (a) include a primer set capable of amplifying each of one or more target nucleic acids and a primer set capable of amplifying a control nucleic acid.
Step (a) may be a step of performing a nucleic acid amplification reaction, using a set of tagged primers as the above-described primers, so as to prepare an amplification reaction product, to which two types of tags have been added.
The tagged primer means a primer used in nucleic acid amplification, to which a tag is added. This tagged primer can be used for the purpose of preparing a tagged amplification reaction product.
The primer used in one or more embodiments of the present invention is a single-stranded nucleic acid consisting of 5 to 80 nucleotides, which specifically recognizes a target nucleic acid or a control nucleic acid and serves as an origin of elongation in a nucleic acid amplification reaction. Specifically, the nucleotide sequence of each primer is a sequence hybridizable with the 3′-terminal side of the target nucleotide sequence (the nucleotide sequence as an amplification target) of a target nucleic acid or a control nucleic acid, or with the 3′-terminal side of the complementary nucleotide sequence of the target nucleotide sequence, and in general, it is a nucleotide sequence complementary to the nucleotide sequence of the 3-terminal side of the target nucleotide sequence, or a nucleotide sequence complementary to the 3′-terminal side of the complementary nucleotide sequence of the target nucleotide sequence. Herein, the “target nucleotide sequence” means a nucleotide sequence to be detected, or a complementary nucleotide sequence thereof. When the target nucleic acid or control nucleic acid is a double-stranded nucleic acid, the target nucleotide sequence means the nucleotide sequence of either one strand of the double-stranded nucleic acid. As long as the primer can specifically bind to a target nucleic acid or a control nucleic acid, the primer may have a deletion or insertion of nucleotides, and a mismatch portion. Herein, the “3′-terminal side” of a predetermined nucleotide sequence means a partial nucleotide sequence consisting of a plurality of consecutive nucleotides (typically, 5 to 80 nucleotides) comprising the nucleotide at the 3′-terminus of the predetermined nucleotide sequence.
In one or more embodiments of the present invention, the phrase “nucleotide sequence X is ‘hybridizable’ with nucleotide sequence Y” means that a polynucleotide (in particular, DNA) comprising the nucleotide sequence X is hybridized with a polynucleotide (in particular, DNA) comprising the nucleotide sequence Y under stringent conditions, and that the polynucleotide comprising the nucleotide sequence X is not hybridized with a polynucleotide that does not comprise the nucleotide sequence Y. That is to say, the term “hybridize” means specific hybridization. Herein the “stringent conditions” mean conditions in which, what is called, a specific hybrid is formed and a non-specific hybrid is not formed. The stringent conditions can be determined depending on, for example, the melting temperature Tm (° C.) of the primer used in one or more embodiments of the present invention and a complementary strand thereof, and the salt concentration in a hybridization solution. Such stringent conditions can be determined with reference to, for example, Green and Sambrook, Molecular Cloning, 4th Ed (2012), Cold Spring Harbor Laboratory Press. Specifically, the stringent conditions can be determined based on the temperature and the salt concentration in a solution, which are applied during Southern hybridization, and the temperature and the salt concentration in a solution, which are applied during the washing step of Southern hybridization. More specifically, the stringent conditions, which are applied, for example, in a hybridization step, may be a sodium concentration of 25 to 500 mM, or 25 to 300 mM, and a temperature that is slightly lower than Tm determined from the polynucleotide sequence (e.g., a temperature that is 0° C. to approximately 5° C. lower than Tm), for example, 40° C. to 68° C., or 40° C. to 65° C. Further specifically, hybridization can be carried out at 1 to 7×SSC, at 0.02% to 3% SDS, and at a temperature of 40° C. to 60° C. Moreover, after completion of the hybridization, a washing step may be carried out. Such a washing step can be carried out, for example, at 0.1 to 2×SSC, at 0.1% to 0.3% SDS, and at a temperature of 50° C. to 65° C.
Primers for amplifying a target nucleic acid are configured to generate a target nucleic acid, to which a labeling tag and a tag for binding to a solid phase carrier bind, as an amplification reaction product. Accordingly, a pair of tagged primers can be used herein as primers. In addition, in a case where a tag is not added to either one of or both of a pair of primers, a nucleic acid amplification reaction reagent comprising a tagged nucleotide source can be used, such that the amplification reaction of a target nucleic acid can generate an amplification reaction product comprising tagged nucleotides.
Similarly, primers for amplifying a control nucleic acid are configured to generate a control nucleic acid, to which a labeling tag and a tag for binding to a solid phase carrier bind, as an amplification reaction product. Accordingly, a pair of tagged primers can be used herein as primers. In addition, in a case where a tag is not added to either one of or both of a pair of primers, a nucleic acid amplification reaction reagent comprising a tagged nucleotide source can be used, such that the amplification reaction of a control nucleic acid can generate an amplification reaction product comprising tagged nucleotides.
Herein, the “labeling tag” means a tag capable of binding to the below-described labeled probe. On the other hand, the “tag for binding to a solid phase carrier” means a tag capable of binding to a probe immobilized on the below-described solid phase carrier.
The tag is a substance used to label an amplification reaction product or a substance used to bind an amplification reaction product to a solid phase, wherein the substance does not generate signals by itself. Examples of such a tag include a nucleic acid, a biotin, a hapten such as DIG (digoxigenin) or FITC (fluorescein isothiocyanate), and a sugar chain. When a single-stranded nucleic acid is used as a tag, it may be possible to insert a spacer structure consisting of a polymerase reaction inhibition region between a tag and a primer, such that the nucleic acid cannot be converted to a double-stranded nucleic acid by a nucleic acid amplification reaction. The spacer structure consisting of a polymerase reaction inhibition region is not particularly limited, as long as it is able to inhibit a nucleic acid elongation reaction by polymerase and is able to keep the single-stranded structure of the tag. Examples of the spacer structure include insertion of various types of natural or non-natural modifications, such as azobenzene modification, alkylene chain or polyoxyalkylene chain modification, and inverted nucleotide modification. The number of nucleotides in the nucleic acid used as a tag is not particularly limited. The number of nucleotides can be, for example, 5 to 80. Examples of the tagged nucleotide source include dNTPs (dUTP, dCTP, etc.) to which biotin or the above-described hapten is bound.
The nucleic acid amplification reaction used in one or more embodiments of the present invention includes a PCR method as a typical example. The present nucleic acid amplification reaction is not particularly limited, as long as it amplifies a specific nucleic acid sequence. In addition to the PCR method, examples of the nucleic acid amplification reaction include known methods such as LCR (Ligase Chain Reaction) method, SDA (Strand Displacement Amplification) method, RCA (Rolling Circle Amplification) method, CPT (Cycling Probe Technology) method, Q-Beta Replicase Amplification Technology method, ICAN (Isothermal and Chimeric primer-initiated Amplification of Nucleic Acids) method, LAMP (Loop-Mediated Isothermal Amplification of DNA) method, NASBA (Nucleic acid Sequence-based Amplification method) method, TMA (Transcription mediated amplification method) method, RPA (Recombinase Polymerase Amplification) method, and SIBA (Strand Invasion Based Amplification) method. The Q-Beta Replicase Amplification Technology method, the RCA method, the NASBA method, the SDA method, the TMA method, the LAMP method, the ICAN method, the RPA method, the SIBA method and the like are methods in which an amplification reaction is carried out at a constant temperature. Other methods, such as the PCR method or the LCR method, are methods in which an amplification reaction is carried out in a temperature cycling system.
The nucleic acid amplification reaction reagent used in the nucleic acid amplification reaction comprises a nucleic acid amplification enzyme and other components necessary for the nucleic acid amplification reaction.
The enzyme used in the nucleic acid amplification reaction is not particularly limited, and commercially available polymerase or other enzymes can be used. Examples of the nucleic acid amplification enzyme include E. coli-derived DNA polymerase 1, T4 DNA polymerase, T7 DNA polymerase, Taq DNA polymerase, KOD DNA polymerase, Pfu DNA polymerase, Bst DNA polymerase, Bsu DNA polymerase, Phi29 DNA polymerase, Bca BEST DNA polymerase, reverse transcriptase, SP6 RNA polymerase, T7 RNA polymerase, and T3 RNA polymerase, but are not limited thereto.
Other components comprised in the nucleic acid amplification reaction reagent will be described later.
In the above-described step (a), at least one target nucleic acid (in a case where target nucleic acids are present in the template nucleic acids) and a control nucleic acid, to each of which two types of tags have been added, are obtained as nucleic acid amplification products. In each target nucleic acid or control nucleic acid, the above-described two types of tags are a labeling tag and a tag used for binding to a solid phase carrier, as described above. The nucleic acid amplification products of each target nucleic acid and control nucleic acid obtained in step (a) are generally nucleic acid amplification products, in which each target nucleic acid or control nucleic acid has been double-stranded, and the above-described two types of tags have been added thereto.
<Steps of Detecting Nucleic Acid (Steps (b), (c) and (d))>
The nucleic acid detection method as described herein comprises the following step (b), (c) and (d), in addition to the above described step (a):
(b) a step of allowing the at least one target nucleic acid to bind to a probe immobilized on a target detection portion on a solid phase carrier,
(c) a step of allowing the at least one target nucleic acid and the control nucleic acid to bind to at least one probe immobilized on a control detection portion on the solid phase carrier, and
(d) a step of labeling the captured target nucleic acid and control nucleic acid, and detecting signals derived from the target nucleic acid and the control nucleic acid.
The order of carrying out these steps (b), (c) and (d), which are carried out after completion of the step (a), is not particularly limited, and a part of or all of these steps may be simultaneously carried out.
In the present description, the steps (b), (c) and (d) are collectively referred to as a “nucleic acid detection step.”
In the nucleic acid detection step, typically, one tag of the two types of tags-added amplification reaction products (target nucleic acids and a control nucleic acid) obtained in the above-described amplification step is first allowed to bind to a labeled probe to form a complex, and thereafter, the other tag is used to capture the complex on a solid phase carrier, so that signals derived from the amplification reaction products are detected.
The probe used in one or more embodiments of the present invention is a substance capable of specifically binding to a tag. Examples of the probe include an antibody reacting with a hapten tag such as DIG or FITC, avidin reacting with a biotin tag (which may also be streptavidin), and a complementary strand reacting with a single-stranded nucleic acid. However, the probe is not limited to the aforementioned substances, as long as it specifically recognizes and binds to the tag. The probe used in one or more embodiments of the present invention may be a protein such as an antibody or avidin, or a nucleic acid such as a complementary strand reacting with a single-stranded nucleic acid tag. The number of nucleotides in the nucleic acid used as a probe is not particularly limited, and it is, for example, 5 to 80.
The labeled probe used in one or more embodiments of the present invention is a probe that binds to a labeling substance emitting signals for detection. As such a labeling substance, a conventionally known substance can be selected, as appropriate, and can be used. Examples of the labeling substance include a fluorescent compound, a radioisotope, an electrochemically active compound, colloidal gold particles, colored particles, and coloring agents such as a pigment or a dye. Detection of signals in the step (d) may be carried out by a method that depends on a labeling substance. Detection of signals can be carried out using a measurement device or by visual inspection. For example, when colloidal gold particles are used as labeling substances, a red color generated as a result of agglutination of the colloidal gold particles is detected as signals.
In one or more embodiments of the present invention, the amplification reaction product (which may be a complex of the amplification reaction product and a labeled probe) is captured on a solid phase carrier by the binding of one tag added to the amplification reaction product with a probe immobilized on the solid phase carrier. The method of immobilizing a probe on the solid phase carrier is not particularly limited in one or more embodiments of the present invention. For example, a single-stranded nucleic acid probe may be immobilized on the carrier via the 3′-terminus thereof, may also be immobilized thereon via the 5′-terminus thereof, may also be immobilized thereon via a portion other than each-terminal portion thereof, may also be immobilized via one or more portions thereof, or may also be immobilized thereon via a protein. An example of the immobilization method involving the use of a protein is a method of utilizing, what is called, a biotin-avidin reaction, wherein the method comprises coating a solid phase carrier with streptavidin and then immobilizing a biotin-modified probe thereon. The probe immobilized on the solid phase carrier may have a suitable spacer, with respect to the surface of the carrier.
As one embodiment of the nucleic acid detection device of one or more embodiments of the present invention, a schematic figure of a lateral flow-type device (100) is shown (the plan view is shown in
The lateral flow-type device (100) shown in
In one or more embodiments of the present invention, the target detection portion (4) mean a portion, in which a probe specifically capturing the tagged amplification reaction product derived from a target nucleic acid is immobilized. On the other hand, the control detection portion (5) means a portion, in which at least one probe specifically capturing target nucleic acid-derived amplification reaction products, as well as a probe specifically capturing the tagged amplification reaction product derived from a control nucleic acid, are immobilized. The type and number of target nucleic acid-derived amplification reaction products captured by the control detection portion are not particularly limited.
In one or more embodiments of the present invention, the position of the control detection portion is not particularly limited. In the case of a lateral flow-type device or a dip stick-type device, the control detection portion may be positioned downstream of the target detection portion.
The sample pad (1), the conjugate pad (2), the solid phase carrier (3) and the absorbent pad (6) each consist of a material such as plastic, glass, cellulose, nitrocellulose, nylon, polyether sulfone, polyvinylidene fluoride, or a porous body such as a filter. The aforementioned components may be constituted with the same material, or may also be constituted with different materials. Moreover, the shape of the carrier is not particularly limited, and it may be a tabular shape.
The amplification reaction product to which two types of tags have been added, obtained by the nucleic acid amplification step, is added to the sample pad (1). Regarding the method of adding the amplification reaction product, the reaction solution obtained after completion of the nucleic acid amplification reaction may be directly added dropwise to the sample pad, or the obtained reaction solution may be mixed with a suitable development solution (e.g., a phosphate buffer, a Tris buffer, a Good's buffer, or an SSC buffer) and the mixed solution may be then added dropwise to the sample pad. The development solution can further comprise a surfactant, salts, a protein, a sugar, a nucleic acid, and the like, as necessary. The tagged amplification reaction product added to the sample pad (1) is developed by capillary phenomenon from the direction of the sample pad (1) to the absorbent pad (6), as shown in
The amplification reaction product, to which two types of tags have been added, is allowed to come into contact with a labeled probe, when it is passed through the conjugate pad (2) containing the labeled probe, and the amplification reaction product binds to the labeled probe via one tag thereof.
Subsequently, when the labeled probe-bound amplification reaction product is passed through the solid phase carrier (3), it is captured on the solid phase carrier via the binding of the other tag thereof with a probe immobilized on the solid phase carrier. The control nucleic acid-derived amplification reaction product is captured only in the control detection portion (5) on the solid phase carrier, whereas the target nucleic acid-derived amplification reaction product is captured both in the target detection portion (4) and in the control detection portion (5) on the solid phase carrier. Thereby, in a detection using a nucleic acid detection device of utilizing multiplex PCR, the target nucleic acids may be amplified under conditions in which large quantities of target nucleic acids are present in the reaction system, and even in a case where the amplification reaction of the control nucleic acid is inhibited, target nucleic acid-derived amplification reaction products are captured not only in the target detection portion, but also in the control detection portion, and the products emit signals. Thus, it becomes possible to prevent the disappearance or reduction of signals from the control detection portion.
It is to be noted that the means for achieving the object is not limited only to the means for providing a device in which two or more types of probes are immobilized on a control detection portion. Any means preventing the disappearance or reduction of signals from a control detection portion may be employed. For example, a device may be used, in which one type of probe is immobilized on the control detection portion. Tagged primers are designed in such a manner that a target nucleic acid is amplified to produce two types of amplified products of the target nucleic acid, namely, a tagged target nucleic acid to be specifically captured on the target detection portion and a tagged target nucleic acid to be specifically captured on the control detection portion, and thus, a multiplex PCR system can be constructed. Thereby, even if there is used a device in which one type of probe is immobilized on the control detection portion, one of the aforementioned two types of amplification reaction products is captured on the detection portion.
With regard to the judgment of the results by using the nucleic acid detection device as described herein, signals derived from the target nucleic acid and the control nucleic acid, which have been subjected to the amplification and/or labeling reactions, are detected using a measurement device or by visual inspection, and the judgment is then carried out based on the obtained results. For example, when colloidal gold particles are used as labeling substances, red coloration occurring with agglutination of the colloidal gold particles is detected as signals, and the judgment is then carried out.
Other shapes of the nucleic acid detection device of one or more embodiments of the present invention include a dip stick-type nucleic acid detection device (100) shown in
The nucleic acid detection device of one or more embodiments of the present invention may be a detection kit comprising reagents necessary for nucleic acid detection, such as a control template nucleic acid, a nucleic acid amplification enzyme, a nucleic acid amplification reaction reagent, and a nucleic acid detection reaction reagent, in addition to the nucleic acid detection device. The preservation state of the control template nucleic acid comprised in the present kit is not particularly limited, and it is any state such as a liquid, a frozen product, or a dried product. The detection kit may further comprise the above-described primers.
The nucleic acid amplification reaction reagent comprises components such as a nucleic acid amplification enzyme, a substrate and a buffer. Examples of the substrate include dATP, dTTP, dCTP, dGTP, dUTP, biotin-labeled dCTP, and biotin-labeled dUTP, but are not limited thereto. As a buffer, a buffer containing, for example, magnesium, potassium, a buffer agent, a surfactant, a reducing agent may be used. The preservation state of the nucleic acid amplification reaction reagent is not particularly limited, and it is any state such as a liquid state, a frozen state, a dried state, or a freeze-dried state.
The nucleic acid detection reaction reagent (nucleic acid detection reagent) is not particularly limited, as long as it is a reagent used in detection. Examples of the nucleic acid detection reaction reagent include the aforementioned development solution, a labeled antibody solution, a coloring substrate solution, and a fluorescent substrate solution, but are not limited thereto. The preservation state may be any state such as a liquid state or a frozen state.
Hereinafter, one or more embodiments of the present invention will be specifically described in the following examples. However, these examples are not intended to limit the technical scope of the present invention.
In the following Examples and Comparative Examples, as a nucleic acid detection device, a nucleic acid detection device 100 having the embodiment shown in
5.5 ml of Gold Colloid (40 nm,9.0×1010 (particles/ml)) (manufactured by British Biocell International) was mixed with 60 μl of 100 μM thiolated DNA (SEQ ID NO: 1), and the obtained mixture was then incubated at 50° C. for 16 hours. Sixteen hours later, 250 μl of 0.1 M phosphate buffer (pH 7.0) and 150 μl of 1 M NaCl were added to the reaction mixture, and the thus obtained mixture was then incubated at 50° C. for 24 hours. Twenty-four hours later, the reaction mixture was centrifuged (5000 G, 15° C., 20 minutes), and a supernatant was then removed. Thereafter, 6 ml of 5 mM phosphate buffer (pH 7.0) was added to the residue, followed by mixing by inverting. Thereafter, the resultant was centrifuged again (5000 G, 15° C., 20 minutes). After that, 6 ml of a supernatant was removed, and 1.5 ml of 5 mM phosphate buffer (pH 7.0) was then added to the residue. The obtained solution was defined as a labeled probe solution, in which thiolated DNA bound to colloidal gold particles. The prepared solution was added to a glass fiber-made pad, so that the solution became homogeneous, and it was then dried in a vacuum dryer. The resultant was defined as a conjugate pad 2 comprising a labeled probe.
The following thiolated DNA was used in the present step.
The nucleic acid detection device 100 used in the present example has a target detection portion 4 and a control detection portion 5, which are disposed in a line from upstream of a solid phase carrier 3.
The target detection portion 4 was produced by applying, in a line, a mixed solution of 200 μl of 100 μM probe A (SEQ ID NO: 2), 200 μl of 2.5 mg/ml streptavidin, 100 μl of 1% BSA solution and 500 μl of 5 mM phosphate buffer to two sites on a nitrocellulose membrane 3 (brand name: Hi-Flow 180, manufactured by Millipore) used as a solid phase carrier, using a dispenser, and then air-drying at 40° C. for 30 minutes. The control detection portion 5 was produced by applying, in a line, a mixed solution of 200 μl of 100 μM probe A (SEQ ID NO: 2), 200 μl of 100 μM probe B (SEQ ID NO: 3), 200 μl of 2.5 mg/ml streptavidin, 100 μl of 1% BSA solution and 300 μl of 5 mM phosphate buffer to two sites on the nitrocellulose membrane 3 used as a solid phase carrier, using a dispenser, and then air-drying at 40° C. for 30 minutes.
The following probes were used in the present step.
The nitrocellulose membrane 3 used as a solid phase carrier produced in the above (2) of the present example, the conjugate pad 2 produced in the above (1) of present example, a commonly used sample pad 1 used as a sample addition portion, and an absorbent pad 6 for absorbing the developed sample or labeling substance were adhered to a base material 110 consisting of a backing sheet, so as to produce a nucleic acid detection device 100 capable of detecting an amplification reaction product obtained by the amplification step.
A nucleic acid detection device 100 was produced by the same method as that applied in Example 1, with the exception that a mixed solution of 200 μl of 100 μM probe B (SEQ ID NO: 3), 200 μl of 2.5 mg/ml streptavidin, 100 μl of 1% BSA solution and 300 μl of 5 mM phosphate buffer was applied in a line to the control detection portion 5. The nucleic acid detection device 100 of Comparative Example 1 has the same structure as that of the nucleic acid detection device 100 of Example 1, with the exception that the probe disposed in the control detection portion 5 was different from that in Example 1.
In the present example, pUC19 (manufactured by Takara Bio, Inc.) shown in SEQ ID NO: 4 was employed as a target nucleic acid that is a detection target, and λ phage DNA (manufactured by Eurofins Genomics K. K.) shown in SEQ ID NO: 5 was employed as a control nucleic acid. These nucleic acids were used as templates and subjected to PCR using single-stranded nucleic acid tagged primers. The amplification reaction products were then applied to the device 100 produced in Example 1, and color signals emitted from a complex formed by binding the amplification reaction products with a labeled probe were then detected. The detection is illustrated in
The single-stranded nucleic acid tagged primer used in the present study consists of a primer part able to bind to each nucleic acid to be amplified, and a single-stranded nucleic acid tag that has been added to the 5′-terminal side of the primer part via a polymerase reaction inhibition region (X).
As primer parts for amplifying pUC19, a pUC19 forward primer (SEQ ID NO: 6) and a pUC19 reverse primer (SEQ ID NO: 7) were designed. Likewise, as primer parts for amplifying λ phage DNA, a λ phage DNA forward primer (SEQ ID NO: 12) and a λ phage DNA reverse primer (SEQ ID NO: 13) were designed.
Moreover, to the 5′-terminal side of each primer part, a single-stranded nucleic acid tag was bound via azobenzene used as a polymerase reaction inhibition region (X), so as to design a single-stranded nucleic acid tagged primer. Regarding single-stranded nucleic acid tagged primers for pUC19, a primer T1-X-F1 (SEQ ID NO: 10), in which a single-stranded nucleic acid tag T1 (SEQ ID NO: 8) was added to the 5′-terminal side of the pUC19 forward primer via azobenzene, and a primer T2-X-R1 (SEQ ID NO: 11), in which a single-stranded nucleic acid tag T2 (SEQ ID NO: 9) was added to the pUC19 reverse primer, were designed. Regarding single-stranded nucleic acid tagged primers for λ phage DNA, a primer T3-X-F2 (SEQ ED NO: 15), in which a single-stranded nucleic acid tag T3 (SEQ ID NO: 14) was added to the λ phage DNA forward primer, and a primer T2-X-R2 (SEQ ID NO: 16), in which a single-stranded nucleic acid tag T2 (SEQ ID NO: 9) was added to the λ phage DNA reverse primer, were designed.
The sequences of the primers designed in the present study are as follows.
It is to be noted that X is represented by the following formula (X).
Using the above-described primer sets, PCR was carried out. 15 pg of the primer set shown in SEQ ID NOs: 10 and 11 and 15 pg of the primer set shown in SEQ ID NOs: 15 and 16, 10 pg of pUC19, and 1 pg of λ phage DNA were added into a 0.2-ml PCR tube, and 100 μl of PCR sample solution (A) was prepared according to the instruction manual of TaKaRa Ex Taq® (manufactured by Takara Bio, Inc.). Similarly, PCR sample solution (B) comprising the above-described primer set, 100 pg of pUC19 and 1 pg of λ phage DNA, and PCR sample solution (C) comprising the above-described primer set, 1000 pg of pUC19 and 1 pg of λ phage DNA, were prepared. Thereafter, each tube was equipped into a thermal cycler (GeneAmp PCR System 9700 (manufactured by Applied Biosystem)). The sample solution was subjected to a heat treatment at 95° C. for 5 minutes, and was then treated at 95° C. for 30 seconds, at 55° C. for 30 seconds, and at 72° C. for 30 seconds, for 35 cycles, so as to obtain an amplification reaction product. In addition, a solution comprising sterilized water and 1 pg of λ phage DNA, instead of pUC19, was prepared, and PCR was then carried out thereon in the same manner as described above, so as to obtain a negative control (D).
The amplification reaction products prepared from the samples (A) to (D) in the above (2) of the present example were not denatured by any denaturing treatment such as heating, but were directly applied to a sample pad 1 of the nucleic acid detection device 100 produced in Example 1, and thereafter, a detection test was carried out. The results were judged by measuring the color intensity of a line using a chromatoreader C10066-10 (manufactured by Hamamatsu Photonics K. K.) 10 minutes after application of each product. The results are shown in Table 1. In addition, the judgment criteria for the measurement values obtained by the chromatoreader are shown in Table 2. In Table 2, the symbol
⊚
indicates a degree in which the color is extremely dense and thus it can be easily confirmed by visual inspection; the symbol
◯
indicates a degree in which the color is thinner than
⊚
but it can be easily confirmed by visual inspection; the symbol
Δ
indicates a degree in which the color is thin and confirmation by visual inspection is still possible but slightly difficult; and the symbol
χ
indicates a degree in which the color is not developed and thus confirmation by visual inspection is impossible. In the present descriptions,
⊚
may be indicated as “4,”
◯
may be indicated as “3,”
Δ
may be indicated as “2,” and
χ
may be indicated as “1.”
indicates data missing or illegible when filed
Color signals were detected by the same method as that applied in Example 2, with the exception that the device 100 produced in Comparative Example 1 was used. The detection is illustrated in
Two types of probes 8 and 9, wherein the probe 8 was the same probe as that immobilized on the target detection portion 4, were immobilized on the control detection portion 5 of the device 100 produced in Example 1. Accordingly, signals derived from the target nucleic acid detected in the target detection portion 4 could also be detected in the control detection portion 5. Thereby, it was demonstrated that a reduction in signals from the control detection portion 5 caused by amplification of the target nucleic acids can be prevented, and that signals from the control detection portion 5 can be easily detected even in a case where large quantities of target nucleic acids are present (e.g. 1000 pg). On the other hand, in the case of using the device 100 produced in Comparative Example 1, when large quantities of target nucleic acids were present (e.g. 1000 pg), signals from the control detection portion 5 disappeared, and whether the PCR had been appropriately carried out could not be judged.
Using a solution of Gold Colloid (streptavidin conjugate, 80 nm, 9.0×1010 (particles/ml)) (manufactured by Funakoshi Co., Ltd.), which had been 8-fold diluted with 1% BSA solution, a conjugate pad 2 was produced by the same method as that applied in Example 1(1).
A mixed solution of 200 μl of 100 μM probe A (SEQ ID NO: 2), 200 μl of 1 M NaCl, 100 μl of 1% BSA solution and 500 μl of 5 mM phosphate buffer was applied to a target detection portion 4, and a mixed solution of 200 μl of 100 μM probe A (SEQ ID NO: 2), 200 μl of 100 μM probe B (SEQ ID NO: 3). 200 μl of 1 M NaCl, 100 μl of 1% BSA solution and 300 μl of 5 mM phosphate buffer was applied to a control detection portion 5, and thereafter, each probe-immobilized solid phase carrier 3 was produced by the same method as that applied in Example 1(2).
A nucleic acid detection device 100 was produced by the same method as that applied in Example 1(3), using a base material 110 consisting of a backing sheet, a nitrocellulose membrane 3 on which the probe produced in Example 1(2) was immobilized, and the conjugate pad 2 produced in the above (1) of the present example.
A nucleic acid detection device 100 was produced by the same method as that applied in Example 3, with the exception that a mixed solution of 200 μl of 100 μM probe B (SEQ ID NO: 3), 200 μl of 1 M NaCl, 100 μl of 1% BSA solution and 300 μl of 5 mM phosphate buffer was applied in a line to the control detection portion 5.
As with Example 2, pUC19 (manufactured by Takara Bio, Inc.) was employed as a target nucleic acid to be detected, and λ phage DNA (manufactured by Eurofins Genomics K. K.) was employed as a control nucleic acid. Using each of these nucleic acids as a template, PCR was carried out with a single-stranded nucleic acid tagged forward primer and a biotin-modified reverse primer. Thereafter, the amplification reaction product was applied to the device 100 produced in Example 3, and color signals emitted from a complex formed by binding the amplification reaction product with a labeled probe were detected. The detection is illustrated in
As a pUC19 forward primer, the primer shown in SEQ ID NO: 10, which had been designed in Example 2(1), was selected. As a pUC19 reverse primer, a primer Biotinylated-R1 (SEQ ID NO: 17), in which the 5′-terminal side of a primer part was modified with biotin, was designed. As a λ phage DNA forward primer, the primer shown in SEQ ID NO: 15 designed in Example 2(1) was selected. As a λ phage DNA reverse primer, a primer Biotinylated-R2 (SEQ ID NO: 18), in which the 5′-terminal side of a primer part was modified with biotin, was designed.
These single-stranded nucleic acid tagged primers and biotin-modified primers were synthesized by TSUKUBA OLIGO SERVICE CO., LTD., and were then acquired from the company.
The primer set designed in the present study is shown below.
The samples (A) to (D) were prepared according to the preparation method described in Example 2(2), using the primer set shown in SEQ ID NOs: 10 and 17 and the primer set shown in SEQ ID NOs: 15 and 18, which had been designed in the above (1). Thereafter, PCR was carried out under the same conditions as those in Example 2(2).
The amplification reaction products prepared from the samples (A) to (D) in the above (2) of the present example were not denatured by any denaturing treatment such as heating, but were directly applied to a sample pad 1 of the nucleic acid detection device 100 produced in Example 3, and thereafter, a detection test was carried out. The results were judged by measuring the color intensity of a line using a chromatoreader C10066-10 (manufactured by Hamamatsu Photonics K. K.) 10 minutes after application of each product. The results are shown in Table 3.
indicates data missing or illegible when filed
Color signals were detected by the same method as that applied in Example 4, with the exception that the device 100 produced in Comparative Example 3 was used. The detection is illustrated in
Two types of probes 8 and 9, wherein the probe 8 was the same probe as that immobilized on the target detection portion 4, were immobilized on the control detection portion 5 of the device 100 produced in Example 3. Accordingly, signals derived from the target nucleic acid detected in the target detection portion 4 could also be detected in the control detection portion 5. Thereby, it was demonstrated that a reduction in signals from the control detection portion 5 caused by amplification of the target nucleic acids can be prevented, and that signals from the control detection portion 5 can be easily detected even in a case where large quantities of target nucleic acids are present (e.g. 1000 pg). On the other hand, in the case of using the device 100 produced in Comparative Example 3, when large quantities of target nucleic acids were present (e.g. 1000 pg), signals from the control detection portion 5 disappeared, and whether the PCR had been appropriately carried out could not be judged.
As with Example 2, pUC19 (manufactured by Takara Bio, Inc.) was employed as a target nucleic acid, and λ phage DNA (manufactured by Eurofins Genomics K. K.) was employed as a control nucleic acid. These nucleic acids were used as templates. Using the templates, a primer set, and dNTP comprising biotin-labeled 16-dUTP (manufactured by Roche Applied Science) as a reaction substrate, PCR was carried out. Thereafter, the amplification reaction product was applied to the device 100 produced in Example 3, and color signals emitted from a complex formed by binding the amplification reaction product with a labeled probe were detected. The detection using the device 100 produced in Example 3 is illustrated in
As a pUC19 forward primer, the primer shown in SEQ ID NO: 10 was selected, and as a pUC19 reverse primer, the primer shown in SEQ ID NO: 7 was selected. On the other hand, as a λ phage DNA forward primer, the primer shown in SEQ ID NO: 15 was selected, and as a λ phage DNA reverse primer, the primer shown in SEQ ID NO: 13 was selected.
(2) PCR Using Single-Stranded Nucleic Acid Tagged Primers and Biotin-Labeled 16-dUTP
PCR was carried out using the above-described primer set. The samples (A) to (D) were prepared according to the preparation method described in Example 2(2), using the primer set shown in SEQ ID NOs: 7 and 10, the primer set shown in SEQ ID NOs: 13 and 15, dNTP included with TaKaRa Ex Taq® (manufactured by Takara Bio, Inc.), and also, biotin-labeled 16-dUTP (manufactured by Roche Applied Science). Thereafter, PCR was carried out under the same conditions as those in Example 2(2).
The amplification reaction products prepared from the samples (A) to (D) in the above (2) of the present example were not denatured by any denaturing treatment such as heating, but were directly applied to a sample pad 1 of the nucleic acid detection device 100 produced in Example 3, and thereafter, a detection test was carried out. The results were judged by measuring the color intensity of a line using a chromatoreader C10066-10 (manufactured by Hamamatsu Photonics K. K.) 10 minutes after application of each product. The results are shown in Table 4.
indicates data missing or illegible when filed
Color signals were detected by the same method as that applied in Example 5, with the exception that the device 100 produced in Comparative Example 3 was used. The detection is illustrated in
Two types of probes 8 and 9, wherein the probe 8 was the same probe as that immobilized on the target detection portion 4, were immobilized on the control detection portion 5 of the device 100 produced in Example 3. Accordingly, signals derived from the target nucleic acid detected in the target detection portion 4 could also be detected in the control detection portion 5. Thereby, it was demonstrated that a reduction in signals from the control detection portion 5 caused by an increase in the target nucleic acids can be prevented, and that signals from the control detection portion 5 can be easily detected even in a case where large quantities of target nucleic acids are present (e.g. 1000 pg). On the other hand, in the case of using the device 100 produced in Comparative Example 3, when large quantities of target nucleic acids were present (e.g. 1000 pg), signals from the control detection portion 5 disappeared, and whether the PCR had been appropriately carried out could not be judged.
As a probe mixed solution to be used in the target detection portion 4, a solution comprising a 2.0 mg/ml of anti-DIG antibody (manufactured by Roche Applied Science), 2.5% sucrose, and 20 mM TBS (pH 8.0) was prepared. As a probe mixed solution to be used in the control detection portion 5, a solution comprising a 1.0 mg/ml of anti-DIG antibody (manufactured by Roche Applied Science) and an anti-FITC antibody (manufactured by Roche Applied Science), 2.5% sucrose, and 20 mM TBS (pH 8.0) was prepared. Using each of the prepared solutions, a probe-immobilized solid phase carrier 3 was produced by the same method as that applied in Example 1(2).
A nucleic acid detection device 100 was produced by the same method as that applied in Example 1(3), using a base material 110 consisting of a backing sheet, the nitrocellulose membrane 3 as a solid phase carrier produced in the above (1) of the present example, and the conjugate pad 2 produced in Example 1(1).
A nucleic acid detection device 100 was produced by the same method as that applied in Example 6, with the exception that, as a probe mixed solution used in the control detection portion 5, a mixed solution comprising 2.0 mg/ml of anti-FITC antibody (manufactured by Roche Applied Science), 2.5% sucrose and 20 mM TBS (pH 8.0) was applied in a line to the control detection portion 5.
As with Example 2, pUC19 (manufactured by Takara Bio, Inc.) was employed as a target nucleic acid, and λ phage DNA (manufactured by Evans Genomics K. K.) was employed as a control nucleic acid. These nucleic acids were used as templates. Using the templates and a primer set, PCR was carried out. Thereafter, the amplification reaction product was applied to the device 100 produced in Example 6, and color signals emitted from a complex formed by binding the amplification reaction product with a labeled probe were detected. The detection using the device 100 produced in Example 6 is illustrated in
As a pUC19 forward primer, a primer DIG-F1 (SEQ ID NO: 19), in which the 5′-terminal side of a primer part was modified with DIG, was designed. As a pUC19 reverse primer, the primer shown in SEQ ID NO: 11 was selected. On the other hand, as a λ phage DNA forward primer, a primer FITC-F2 (SEQ ID NO: 20), in which the 5′-terminal side of a primer part was modified with FITC, was designed. As a λ phage DNA reverse primer, the primer shown in SEQ ID NO: 16 was selected.
These DIG-modified primers, FITC-modified primers and single-stranded nucleic acid tagged primers were synthesized by TSUKUBA OLIGO SERVICE CO., LTD., and were then acquired from the company.
The primer set designed in the present study is shown below.
PCR was carried out using the above-described primer set. The samples (A) to (D) were prepared according to the preparation method described in Example 2(2), using the primer set shown in SEQ ID NOs: 11 and 19, and the primer set shown in SEQ ID NOs: 16 and 20. Thereafter, PCR was carried out under the same conditions as those in Example 2(2).
The amplification reaction products prepared from the samples (A) to (D) in the above (2) of present example were not denatured by any denaturing treatment such as heating, but were directly applied to a sample pad 1 of the nucleic acid detection device 100 produced in Example 6, and thereafter, a detection test was carried out. The results were judged by measuring the color intensity of a line using a chromatoreader C10066-10 (manufactured by Hamamatsu Photonics K. K.) 10 minutes after application of each product. The results are shown in Table 5.
indicates data missing or illegible when filed
Color signals were detected by the same method as that applied in Example 6, with the exception that the device 100 produced in Comparative Example 6 was used. The detection is illustrated in
Two types of probes 21 and 22, wherein the probe 22 was the same probe as that immobilized on the target detection portion 4, were immobilized on the control detection portion 5 of the device 100 produced in Example 6. Accordingly, signals derived from the target nucleic acid detected in the target detection portion 4 could also be detected in the control detection portion 5. Thereby, it was demonstrated that a reduction in signals from the control detection portion 5 caused by an increase in the target nucleic acids can be prevented, and that signals from the control detection portion 5 can be easily detected even in a case where large quantities of target nucleic acids are present (e.g. 1000 pg). On the other hand, in the case of using the device 100 produced in Comparative Example 6, when large quantities of target nucleic acids were present (e.g. 1000 pg), signals from the control detection portion 5 disappeared, and whether the PCR had been appropriately carried out could not be judged.
In the present example, we did not apply the method of immobilizing two types of probes, namely, a probe for capturing a control nucleic acid and a probe for capturing a target nucleic acid, on a control detection portion 5, which was applied in the previous examples. In the present example, we constructed an amplification reaction system of producing two types of amplified products of a target nucleic acid having different types of tags, so that we prevented a reduction in signals from the control detection portion 5. Specifically, tagged primers were designed, such that two types of amplified products of a target nucleic acid, namely, a target nucleic acid having a tag to be specifically captured on a target detection portion 4 and a target nucleic acid having a tag to be specifically captured on a control detection portion 5 were amplified, and such that one of the two types of amplified products is captured on the control detection portion 5. The detection of the present example is illustrated in
As with Example 2, pUC19 (manufactured by Takara Bio, Inc.) was used as a target nucleic acid, and λ phage DNA (manufactured by Eurolins Genomics K. K.) was used as a control nucleic acid. After PCR had been carried out, the amplification reaction product was applied to the device 100 produced in Comparative Example 1, and color signals emitted from a complex formed by binding the amplification reaction product with a labeled probe were detected.
In the present study, two types of primer sets were prepared as pUC19 primer sets. As a first primer set, primers shown in SEQ ID NOs: 10 and 11 were selected. In addition, a primer T3-X-F1 (SEQ ID NO: 21) was designed by adding a single-stranded nucleic acid tag T3 (SEQ ID NO: 14) to the 5′-terminal side of the forward primer shown in SEQ ID NO: 6 via azobenzene used as a polymerase reaction inhibition region (X). Thus, as a second primer set, primers shown in SEQ ID NOs: 11 and 21 were selected. As a λ phage DNA primer set, a primer set shown in SEQ ID NOs: 15 and 16 was selected. These single-stranded nucleic acid tagged primers were synthesized by TSUKUBA OLIGO SERVICE CO., LTD., and were then acquired from the company.
The primer designed in the present study is shown below.
The samples (A) to (D) were prepared according to the preparation method described in Example 2(2), using the three types of primer sets, namely, the primer set shown in SEQ ID NOs: 10 and 11, the primer set shown in SEQ ID NOs: 11 and 21, the primer set shown in SEQ ID NOs: 15 and 16, which had been designed in the above (1) of the present example. Using these samples, PCR was carried out under the same conditions as those applied in Example 2(2).
The amplification reaction products prepared from the samples (A) to (D) in the above (2) of the present example were not denatured by any denaturing treatment such as heating, but were directly applied to a sample pad 1 of the nucleic acid detection device 100 produced in Comparative Example 1, and thereafter, a detection test was carried out. The results were judged by measuring the color intensity of a line using a chromatoreader C10066-10 (manufactured by Hamamatsu Photonics K. K.) 10 minutes after application of each product. The results are shown in Table 6.
indicates data missing or illegible when filed
Color signals were detected by the same method as that applied in Comparative Example 2. The detection is illustrated in
In Example 8, two types of target nucleic acids, namely, a target nucleic acid having a tag to be specifically captured on a target detection portion 4 and a target nucleic acid having a tag to be specifically captured on a control detection portion 5, were prepared. As a detection device 100, a device, in which one type of probe was immobilized both on the target detection portion 4 and on the control detection portion 5, was used. Also in the present example, target nucleic acids were detected not only in the target detection portion 4, but also in the control detection portion 5. Thus, as shown in Table 6, signals derived from the target nucleic acids could be detected in the control detection portion 5, even under conditions in which 1000 pg of the target nucleic acids and 1 pg of the control nucleic acid were present. Therefore, it was demonstrated that the disappearance or reduction of signals in the control detection portion 5 can be prevented by preparing target nucleic acids having two types of tags. On the other hand, in Comparative Example 8, when large quantities of target nucleic acids were present (1000 pg), signals from the control detection portion 5 disappeared, and whether PCR had been appropriately carried out could not be judged.
As given above, the invention of the present disclosure is described with reference to embodiments and comparative embodiments. However, the present invention is not limited to the above-described embodiments and comparative embodiments. The present embodiment can also be carried out by applying a detection method using the dip stick-type device 100 or the array-type device 100, or a detection method comprising subjecting the amplified and/or labeled product to a heat treatment and then detecting it in the form of a single strand, or a method of using a sugar chain as a tag and using lection as a probe to be immobilized on a carrier.
All publications, patents and patent applications cited in the present description are incorporated herein by reference in their entirety.
Although the disclosure has been described with respect to only a limited number of embodiments, those skilled in the art, having benefit of this disclosure, will appreciate that various other embodiments may be devised without departing from the scope of the present invention. Accordingly, the scope of the present invention should be limited only by the attached claims.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2015-167198 | Aug 2015 | JP | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/JP2016/074953 | Aug 2016 | US |
| Child | 15905497 | US |
